About
Antibody Therapeutics
Areas of Focus
Categories
Biologics & BiopharmaceuticalAntibodyChina
Clinical Trials (3)
View allTotal Trials
3
As Lead Sponsor
2
As Collaborator
1
Total Enrollment
725
By Phase
PHASE1: 1PHASE1/PHASE2: 2
By Status
RECRUITING: 2NOT_YET_RECRUITING: 1
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2022
2023
2024
2025
2026
2027
2028
2029
Today
Hover over trial bars to see details
Recent Trials
NCT07106827Collaborator
A Study of GV20-0251 in Advanced or Refractory Solid Tumors
PHASE1Not yet recruiting
10 participants
Started: Jul 31, 2025 · Completed: Jun 11, 2028
NCT07070518Lead Sponsor
Study of GV20-0251 in Participants With Solid Tumor Malignancies
PHASE1/PHASE2Recruiting
350 participants
Started: Jul 11, 2025 · Completed: Sep 16, 2028
NCT05669430Lead Sponsor
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
PHASE1/PHASE2Recruiting
365 participants
Started: Mar 23, 2023 · Completed: Sep 5, 2027
Locations (1)
Headquarters
Shanghai, China
Map
Loading map...